Pilot Project

试点项目组件旨在提供一种灵活的方法来开发和探索新的 研究活动或方向，以及可演变为独立资助研究的独特机会 项目。在6-10年期间，我们建议每年资助两个试验项目，预算约为50,000美元 每个项目。这些项目的预计期限为一年；项目可延长至两年 在成功的竞争更新之后。中心科学主任将管理这一部分。引航员 项目申请将每年向EGCRC和加州大学旧金山分校的调查人员征集。每项提案都将是 对科学价值、创新和与中心总体目标的关联性进行至少两次评估 ACTG方案咨询委员会成员、科学主任和中心主任。 将审议资助建议，供中心指导委员会批准。两名飞行员 项目已经提出，并获得了06年的资金。项目7A(A·凯瑟，主任)将 检查Delta阿片受体(DOR)激动剂ALK33是否可以成为治疗酒精的潜在药物 临床前人体试验中的摄取和渴求。在人体受试者身上的实验也旨在进行 功能磁共振成像研究确定是否增加内侧前额叶皮质和 大脑中与奖励和焦虑相关的区域。

The Pilot Project Component is designed to provide a flexible means for developing and exploring new research activities or directions, and unique opportunities that can evolve into independently funded research projects. During Years 6-10 we propose funding two pilot projects per year with a budget of about $50,000 per project. The expected duration of these projects will be 1 year; projects can be extended to two years upon successful competitive renewal. The Center Scientific Director will manage this Component. Pilot Project applications will be solicited annually from EGCRC and UCSF investigators. Each proposal will be evaluated for scientific merit, innovation, and for relatedness to the Center's overall goals by at least two members of the ACTG Program Advisory Board, the Scientific Director, and the Center Director. Recommendations for funding will be considered for approval by the Center Steering Committee. Two Pilot Projects have been proposed and awarded funding for Year 06.Project 7A (A. Kayser, Director) will examine whether the Delta Opioid Receptor (DOR) agonist, ALK33, can be a potential drug to treat alcohol intake and craving in a preclinical human trial. Experiments in human subjects are also aimed to conducted fMRI studies to determine whether the increase the connectivity between the medial prefrontal cortex and brain regions associated with reward and anxiety.